Journal of medicinal and pharmaceutical chemistry 2011-01-13

Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.

Chun-Hsu Yao, Jen-Shin Song, Chiung-Tong Chen, Teng-Kuang Yeh, Ming-Shiu Hung, Chih-Chun Chang, Yu-Wei Liu, Mao-Chia Yuan, Chieh-Jui Hsieh, Chung-Yu Huang, Min-Hsien Wang, Ching-Hui Chiu, Tsung-Chih Hsieh, Szu-Huei Wu, Wen-Chi Hsiao, Kuang-Feng Chu, Chi-Hui Tsai, Yu-Sheng Chao, Jinq-Chyi Lee

Index: J. Med. Chem. 54 , 166, (2011)

Full Text: HTML

Abstract

A novel series of N-linked β-D-xylosides were synthesized and evaluated for inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) in a cell-based assay. Of these, the 4-chloro-3-(4-cyclopropylbenzyl)-1-(β-D-xylopyranosyl)-1H-indole 19m was found to be the most potent inhibitor, with an EC(50) value similar to that of the natural SGLT2 inhibitor phlorizin. Further studies in Sprague-Dawley (SD) rats indicated that 19m significantly increased urine glucose excretion in a dose-dependent manner with oral administration. The antihyperglycemic effect of 19m was also observed in streptozotocin (STZ) induced diabetic SD rats. These results described here are a good starting point for further investigations into N-glycoside SGLT2 inhibitors.